The creation of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, requires a complex several-stage organic process. Preliminary routes focused on amino acid chain section coupling, utilizing solid-phase synthesis methodologies to build the long amino acid sequence. Subsequent research has explored alternative approaches, inc